Iovance Biotherapeutics (IOVA) Projected to Post Earnings on Tuesday

Iovance Biotherapeutics (NASDAQ:IOVA) is expected to be releasing its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Iovance Biotherapeutics to post earnings of ($0.22) per share and revenue of $81.6050 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.

Iovance Biotherapeutics Price Performance

IOVA stock opened at $2.58 on Tuesday. The company’s 50-day moving average is $2.55 and its 200-day moving average is $2.39. The stock has a market capitalization of $1.02 billion, a PE ratio of -2.15 and a beta of 0.76. Iovance Biotherapeutics has a 1 year low of $1.64 and a 1 year high of $6.09.

Institutional Trading of Iovance Biotherapeutics

Large investors have recently made changes to their positions in the company. Granite Investment Partners LLC acquired a new position in Iovance Biotherapeutics during the 4th quarter worth approximately $29,000. Motley Fool Asset Management LLC acquired a new position in shares of Iovance Biotherapeutics during the 4th quarter worth $29,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Iovance Biotherapeutics in the 4th quarter worth about $46,000. HighTower Advisors LLC grew its stake in Iovance Biotherapeutics by 67.9% in the 4th quarter. HighTower Advisors LLC now owns 19,089 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 7,718 shares during the last quarter. Finally, Diversify Wealth Management LLC purchased a new position in Iovance Biotherapeutics during the 2nd quarter valued at about $34,000. 77.03% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IOVA has been the subject of several research reports. The Goldman Sachs Group reissued a “sell” rating and issued a $2.00 price target on shares of Iovance Biotherapeutics in a research report on Thursday, February 5th. Chardan Capital decreased their price objective on Iovance Biotherapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a report on Thursday, November 6th. Barclays lifted their target price on Iovance Biotherapeutics from $9.00 to $10.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Finally, HC Wainwright dropped their price objective on Iovance Biotherapeutics from $20.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, October 29th. Five research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Iovance Biotherapeutics currently has a consensus rating of “Hold” and a consensus price target of $10.50.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.